A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR

BACKGROUND: Oxycodone/naloxone (OXN PR) is a prolonged‐release formulation containing oxycodone and naloxone in a 2:1 ratio. This study aimed to evaluate the tolerability and efficacy of doses up to OXN160/80 mg PR compared with oxycodone prolonged‐release formulation (OxyPR) in a randomised control...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Pain
Main Authors: Dupoiron, D., Stachowiak, A., Loewenstein, O., Ellery, A., Kremers, W., Bosse, B., Hopp, M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5600007/
https://ncbi.nlm.nih.gov/pubmed/28641363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejp.1054
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados